S70 groups of adult acute lymphoblastic leukemia. Blood. 1995;86(6):2091–2097. 3. Reman O, Pigneux A, Huguet F, et al. Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis and/or at first relapse: Results from the GETLALA group. Leuk Res. 2008;32(11):1741–1750. 4. Yao H, Price TT, Cantelli G, et al. Leukemia hijacks a neural mechanism to invade the central nervous system. Nature. 2018;560:55-60. 5. Omura G, Moffitt S, Vogler W, et al. Combination chemotherapy of adult acute lymphoblastic leukemia with randomized central nervous system prophylaxis. Blood. 1980;55(2):199–204. 6. Thomas DA, O’Brien S, Rytting M, et al. Incidence of central nervous system (CNS) relapse in de novo adult acute lymphoblastic leukemia (ALL). Blood. 2014 Dec 6 ;124(21):940–940. 7. Dargenio M, Bonifacio M, Chiaretti S, et el. Incidence, treatment and outcome of central nervous system relapse in adult acute lymphoblastic leukaemia patients treated frontline with paediatric-inspired regimens: A retrospective multicentre Campus ALL study. Br J Haematol. 2023 Feb;200(4):440-450. 8. Samra B, Khoury JD, Morita K, Ravandi F, RichardCarpentier G. Long-term outcome of hyper-CVAD-R for Burkitt leukemia/lymphoma and high-grade B-cell lymphoma: focus on CNS relapse. Blood Adv. 2021 Oct 26;5(20):3913-3918. 9. Kopmar N and Cassaday R. How I prevent and treat central nervous system disease in adults with acute lymphoblastic leukemia. Blood. 2023 Mar 23;141(12):1379-1388. 10. Lazarus HM, Richards SM, Chopra R, et al. Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993. Blood. 2006 Jul 15;108(2):465-72. 11. Sanchez R, Ayala R, Alonso R, et al. Clinical characteristics of patients with central nervous system relapse in BCR-ABL1-positive acute lymphoblastic leukemia: the importance of characterizing ABL1 mutations in cerebrospinal fluid. Ann Hematol. 2017 Jul;96(7):10691075. 12. Paul S, Kantarjian H, Sasaki K, et al. Intrathecal prophylaxis with 12 versus 8 administrations reduces the incidence of central nervous system relapse in patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia. Am J Hematol. 2023 Jan;98(1):E11-E14. 13. Advani AS, Moseley A, O’Dwyer KM, et al. Dasatinib/ prednisone induction followed by blinatumomab/dasatinib in Ph+ acute lymphoblastic leukemia. Blood Adv. 2023 Apr 11;7(7):1279-1285. 14. Thomas DA, Faderl S, O’Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer [Internet]. 2006 Apr 1 [cited 2022 Oct 1];106(7):1569– 80.
RkJQdWJsaXNoZXIy MTk3NTQxMg==